| . | 1HP Regimen (n = 205) . | 3HP Regimen (n = 274) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 43 (34–51) | 43 (35–51) | .417 |
| Male sex, n (%) | 193 (94.1) | 260 (94.9) | .722 |
| Transmission route, n (%) | |||
| Men who have sex with men | 155 (75.6) | 158 (57.7) | <.001 |
| Heterosexuals | 22 (10.7) | 23 (8.4) | .386 |
| Illicit drug use | 28 (13.7) | 94 (34.3) | <.001 |
| Weight, median (IQR), kg | 70.0 (61.0–76.7) | 68.8 (61.1–76.0) | .635 |
| Incarceration, n (%) | 8 (3.9) | 32 (11.7) | .002 |
| Comorbidity, n (%) | |||
| HBsAg positivity | 24 (11.7) | 14 (5.1) | .008 |
| Anti-HCV positivity | 38 (18.5) | 73 (26.6) | .037 |
| Cardiovascular disease | 15 (7.3) | 34 (12.4) | .069 |
| Cerebrovascular disease | 3 (1.5) | 0 (0) | .045 |
| Diabetes mellitus | 12 (5.9) | 17 (6.2) | .873 |
| Chronic kidney diseasea | 3 (1.5) | 2 (0.7) | .434 |
| Chronic obstructive pulmonary disease or asthma | 1 (0.5) | 2 (0.7) | .740 |
| Malignancy | 1 (0.5) | 3 (1.1) | .470 |
| Baseline CD4 countb, median (IQR), cells/mm3 | 658 (503–878) | 636 (487–814) | .186 |
| Baseline PVLc, median (range), log10 copies/mL | UDc (UD-4.74) | UD (UD-4.15) | .383 |
| ART during LTBI treatment, n (%) | … | … | <.001 |
| Bictegravir-containing regimend | 142 (69.3) | 38 (13.9) | |
| Dolutegravir-containing regimene | 46 (22.4) | 214 (78.1) | |
| Othersf | 17 (8.3) | 22 (8.0) | |
| Concurrent medication other than rifapentine decreasing serum concentration of ART, n (%) | 0 (0) | 1 (0.4)g | .387 |
| . | 1HP Regimen (n = 205) . | 3HP Regimen (n = 274) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 43 (34–51) | 43 (35–51) | .417 |
| Male sex, n (%) | 193 (94.1) | 260 (94.9) | .722 |
| Transmission route, n (%) | |||
| Men who have sex with men | 155 (75.6) | 158 (57.7) | <.001 |
| Heterosexuals | 22 (10.7) | 23 (8.4) | .386 |
| Illicit drug use | 28 (13.7) | 94 (34.3) | <.001 |
| Weight, median (IQR), kg | 70.0 (61.0–76.7) | 68.8 (61.1–76.0) | .635 |
| Incarceration, n (%) | 8 (3.9) | 32 (11.7) | .002 |
| Comorbidity, n (%) | |||
| HBsAg positivity | 24 (11.7) | 14 (5.1) | .008 |
| Anti-HCV positivity | 38 (18.5) | 73 (26.6) | .037 |
| Cardiovascular disease | 15 (7.3) | 34 (12.4) | .069 |
| Cerebrovascular disease | 3 (1.5) | 0 (0) | .045 |
| Diabetes mellitus | 12 (5.9) | 17 (6.2) | .873 |
| Chronic kidney diseasea | 3 (1.5) | 2 (0.7) | .434 |
| Chronic obstructive pulmonary disease or asthma | 1 (0.5) | 2 (0.7) | .740 |
| Malignancy | 1 (0.5) | 3 (1.1) | .470 |
| Baseline CD4 countb, median (IQR), cells/mm3 | 658 (503–878) | 636 (487–814) | .186 |
| Baseline PVLc, median (range), log10 copies/mL | UDc (UD-4.74) | UD (UD-4.15) | .383 |
| ART during LTBI treatment, n (%) | … | … | <.001 |
| Bictegravir-containing regimend | 142 (69.3) | 38 (13.9) | |
| Dolutegravir-containing regimene | 46 (22.4) | 214 (78.1) | |
| Othersf | 17 (8.3) | 22 (8.0) | |
| Concurrent medication other than rifapentine decreasing serum concentration of ART, n (%) | 0 (0) | 1 (0.4)g | .387 |
Abbreviations: 1HP, 1 month of daily rifapentine plus isoniazid; 3HP, 3 months of weekly rifapentine plus isoniazid; ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; IQR, interquartile range; LTBI, latent tuberculosis infection; PWH, people with human immunodeficiency virus; PVL, plasma HIV RNA load; UD, undetectable.
aChronic kidney disease was defined as reduced glomerular filtration rate or kidney damage (<60 mL/min/1.73 m2 of body-surface area) for more than 3 months.
bCD4 count was measured with the use of flow cytometry (BD FACS Calibur; Becton Dickinson, CA, USA).
cThe quantification of PVL was conducted using the Cobas AmpliPrep/Cobas TaqMan HIV-1 test (version 2.0; Roche Molecular Systems) with a lower detection limit of 20 copies/mL.
dAll PWH received bictegravir-containing regimens in the form of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
eMost PWH received dolutegravir-containing regimens in the form of coformulated dolutegravir/lamivudine/abacavir (n = 216), followed by coformulated dolutegravir/lamivudine (35), dolutegravir and emtricitabine/tenofovir disoproxil fumarate (7), as well as dolutegravir and lamivudine/zidovudine (2).
fOther ART included coformulated efavirenz/emtricitabine/tenofovir disoproxil fumarate (n = 17) in the 1HP group, as well as efavirenz/emtricitabine/tenofovir disoproxil fumarate (19), rilpivirine/emtricitabine/tenofovir alafenamide (2), and raltegravir plus emtricitabine/tenofovir disoproxil fumarate (1) in the 3HP group. Despite being contraindicated because of reduced rilpivirine exposure [16], 2 individuals chose to continue 3HP treatment with rilpivirine-containing ART after their physician's explanation.
gOne individual had potential drug interaction between dolutegravir and ferric hydroxide polymaltose complex.
| . | 1HP Regimen (n = 205) . | 3HP Regimen (n = 274) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 43 (34–51) | 43 (35–51) | .417 |
| Male sex, n (%) | 193 (94.1) | 260 (94.9) | .722 |
| Transmission route, n (%) | |||
| Men who have sex with men | 155 (75.6) | 158 (57.7) | <.001 |
| Heterosexuals | 22 (10.7) | 23 (8.4) | .386 |
| Illicit drug use | 28 (13.7) | 94 (34.3) | <.001 |
| Weight, median (IQR), kg | 70.0 (61.0–76.7) | 68.8 (61.1–76.0) | .635 |
| Incarceration, n (%) | 8 (3.9) | 32 (11.7) | .002 |
| Comorbidity, n (%) | |||
| HBsAg positivity | 24 (11.7) | 14 (5.1) | .008 |
| Anti-HCV positivity | 38 (18.5) | 73 (26.6) | .037 |
| Cardiovascular disease | 15 (7.3) | 34 (12.4) | .069 |
| Cerebrovascular disease | 3 (1.5) | 0 (0) | .045 |
| Diabetes mellitus | 12 (5.9) | 17 (6.2) | .873 |
| Chronic kidney diseasea | 3 (1.5) | 2 (0.7) | .434 |
| Chronic obstructive pulmonary disease or asthma | 1 (0.5) | 2 (0.7) | .740 |
| Malignancy | 1 (0.5) | 3 (1.1) | .470 |
| Baseline CD4 countb, median (IQR), cells/mm3 | 658 (503–878) | 636 (487–814) | .186 |
| Baseline PVLc, median (range), log10 copies/mL | UDc (UD-4.74) | UD (UD-4.15) | .383 |
| ART during LTBI treatment, n (%) | … | … | <.001 |
| Bictegravir-containing regimend | 142 (69.3) | 38 (13.9) | |
| Dolutegravir-containing regimene | 46 (22.4) | 214 (78.1) | |
| Othersf | 17 (8.3) | 22 (8.0) | |
| Concurrent medication other than rifapentine decreasing serum concentration of ART, n (%) | 0 (0) | 1 (0.4)g | .387 |
| . | 1HP Regimen (n = 205) . | 3HP Regimen (n = 274) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 43 (34–51) | 43 (35–51) | .417 |
| Male sex, n (%) | 193 (94.1) | 260 (94.9) | .722 |
| Transmission route, n (%) | |||
| Men who have sex with men | 155 (75.6) | 158 (57.7) | <.001 |
| Heterosexuals | 22 (10.7) | 23 (8.4) | .386 |
| Illicit drug use | 28 (13.7) | 94 (34.3) | <.001 |
| Weight, median (IQR), kg | 70.0 (61.0–76.7) | 68.8 (61.1–76.0) | .635 |
| Incarceration, n (%) | 8 (3.9) | 32 (11.7) | .002 |
| Comorbidity, n (%) | |||
| HBsAg positivity | 24 (11.7) | 14 (5.1) | .008 |
| Anti-HCV positivity | 38 (18.5) | 73 (26.6) | .037 |
| Cardiovascular disease | 15 (7.3) | 34 (12.4) | .069 |
| Cerebrovascular disease | 3 (1.5) | 0 (0) | .045 |
| Diabetes mellitus | 12 (5.9) | 17 (6.2) | .873 |
| Chronic kidney diseasea | 3 (1.5) | 2 (0.7) | .434 |
| Chronic obstructive pulmonary disease or asthma | 1 (0.5) | 2 (0.7) | .740 |
| Malignancy | 1 (0.5) | 3 (1.1) | .470 |
| Baseline CD4 countb, median (IQR), cells/mm3 | 658 (503–878) | 636 (487–814) | .186 |
| Baseline PVLc, median (range), log10 copies/mL | UDc (UD-4.74) | UD (UD-4.15) | .383 |
| ART during LTBI treatment, n (%) | … | … | <.001 |
| Bictegravir-containing regimend | 142 (69.3) | 38 (13.9) | |
| Dolutegravir-containing regimene | 46 (22.4) | 214 (78.1) | |
| Othersf | 17 (8.3) | 22 (8.0) | |
| Concurrent medication other than rifapentine decreasing serum concentration of ART, n (%) | 0 (0) | 1 (0.4)g | .387 |
Abbreviations: 1HP, 1 month of daily rifapentine plus isoniazid; 3HP, 3 months of weekly rifapentine plus isoniazid; ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; IQR, interquartile range; LTBI, latent tuberculosis infection; PWH, people with human immunodeficiency virus; PVL, plasma HIV RNA load; UD, undetectable.
aChronic kidney disease was defined as reduced glomerular filtration rate or kidney damage (<60 mL/min/1.73 m2 of body-surface area) for more than 3 months.
bCD4 count was measured with the use of flow cytometry (BD FACS Calibur; Becton Dickinson, CA, USA).
cThe quantification of PVL was conducted using the Cobas AmpliPrep/Cobas TaqMan HIV-1 test (version 2.0; Roche Molecular Systems) with a lower detection limit of 20 copies/mL.
dAll PWH received bictegravir-containing regimens in the form of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
eMost PWH received dolutegravir-containing regimens in the form of coformulated dolutegravir/lamivudine/abacavir (n = 216), followed by coformulated dolutegravir/lamivudine (35), dolutegravir and emtricitabine/tenofovir disoproxil fumarate (7), as well as dolutegravir and lamivudine/zidovudine (2).
fOther ART included coformulated efavirenz/emtricitabine/tenofovir disoproxil fumarate (n = 17) in the 1HP group, as well as efavirenz/emtricitabine/tenofovir disoproxil fumarate (19), rilpivirine/emtricitabine/tenofovir alafenamide (2), and raltegravir plus emtricitabine/tenofovir disoproxil fumarate (1) in the 3HP group. Despite being contraindicated because of reduced rilpivirine exposure [16], 2 individuals chose to continue 3HP treatment with rilpivirine-containing ART after their physician's explanation.
gOne individual had potential drug interaction between dolutegravir and ferric hydroxide polymaltose complex.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
